Logo

STSSW

Sharps Technology, Inc.

STSSW

Sharps Technology, Inc. • NASDAQ
$0.06 ▲ 20.48% (+0.01)
Market Cap $1.69 M
52w High $0.07
52w Low $0.06
Dividend Yield 0%
P/E -0.06
Volume 3.05K
Outstanding Shares 28.23M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.289M ▲ $111.537M ▲ $-105.333M ▼ -4.602K% ▼ $-4.33 ▼ $-105.188M ▼
Q2-2025 $222.722K ▲ $1.834M ▼ $3.559M ▲ 1.598K% ▲ $3.58 ▼ $3.7M ▲
Q1-2025 $0 $1.891M ▲ $1.929M ▲ 0% $38.62 ▲ $2.687M ▲
Q4-2024 $0 $1.885M ▲ $-4.526M ▼ 0% $-1.201K ▼ $-4.366M ▼
Q3-2024 $0 $1.821M $-1.685M 0% $-48.94 $-1.491M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $25.718M ▲ $443.96M ▲ $10.746M ▲ $433.214M ▲
Q2-2025 $8.322M ▼ $17.085M ▼ $2.546M ▼ $14.54M ▲
Q1-2025 $11.895M ▲ $18.916M ▲ $8.781M ▲ $10.135M ▲
Q4-2024 $864.041K ▼ $7.314M ▼ $5.318M ▲ $1.996M ▼
Q3-2024 $2.473M $11.254M $4.748M $6.506M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $3.559M ▲ $-1.905M ▲ $-1.486M ▼ $0 ▼ $-3.573M ▼ $-3.775M ▼
Q1-2025 $1.929M ▲ $-2.451M ▼ $-473.658K ▼ $13.953M ▲ $11.031M ▲ $-2.541M ▼
Q4-2024 $-4.526M ▼ $-1.757M ▼ $-93.478K ▼ $199.461K ▼ $-1.609M ▼ $-1.827M ▼
Q3-2024 $-1.685M ▲ $-1.643M ▼ $-50.304K ▲ $2.736M ▼ $989.903K ▲ $-1.694M ▼
Q2-2024 $-2.102M $-1.639M $-1.017M $2.972M $317.38K $-1.656M

Five-Year Company Overview

Income Statement

Income Statement The income statement shows essentially no meaningful revenue for several years and small but consistent operating losses. This looks like a company that has been in a development or transition phase rather than a mature, cash‑generating business. Reported earnings per share have swung sharply, which likely reflects changes in share count and corporate actions more than changes in the underlying business. Overall, the historical picture is of a company consuming capital, not yet producing steady income from operations.

Balance Sheet

Balance Sheet Historically, the balance sheet has been very small, with limited assets, minimal cash reported, no debt, and a thin equity base. That suggests a fragile financial footing in the past. However, the recent large private placement and creation of a digital asset treasury, mostly in Solana tokens, would radically change the balance sheet profile once fully reflected: the company becomes asset‑rich on paper but heavily exposed to crypto price swings. This adds balance sheet strength in one sense, but with much higher volatility and valuation uncertainty.

Cash Flow

Cash Flow Cash flow has been negative from operations over the historical period, with no offsetting investment inflows from a productive asset base. Free cash flow has been weak and consistently negative, which is typical for an early‑stage or repositioning company that has not yet converted its strategy into cash‑generating activities. Going forward, cash flow will likely depend far more on the performance and management of the digital asset treasury and on the success of the new distribution model, rather than on the legacy manufacturing operations that have now been wound down.

Competitive Edge

Competitive Edge Sharps previously built a niche competitive position around patented safety syringes and specialized manufacturing capacity, supported by long‑term supply agreements. That suggested a focused moat in a specific segment of the medical device market. With the company now shifting away from in‑house manufacturing toward a sales and distribution role, part of that manufacturing‑based edge may erode, and Sharps will compete more directly with established distributors and larger device companies. At the same time, the move into being a digital‑asset‑heavy company places it in a very different competitive set, where its edge is less about product and more about capital allocation and risk management. The result is a more complex, less clearly defined competitive position.

Innovation and R&D

Innovation and R&D Historically, Sharps invested in meaningful product innovation, including ultra‑low‑waste safety syringes and copolymer prefillable syringes, backed by multiple patents. This pointed to a company trying to differentiate through engineering and design in a regulated medical field. The recent decision to cease R&D and manufacturing, spin off the Hungarian subsidiary, and focus on distribution marks a sharp break from that innovation‑led model. Future product advances may rely more on partners than on internal research. The main “innovation” now is financial and strategic—using a large Solana‑based treasury as a core asset—rather than developing new medical technologies in‑house.

Summary

Sharps Technology is in the middle of a major transformation. The historical numbers show a tiny, loss‑making operation with no recurring revenue base, built around promising but capital‑intensive medical device innovation. The new strategy pivots away from manufacturing and R&D and toward two very different pillars: medical device distribution and holding a large, volatile crypto asset portfolio. This could significantly strengthen reported assets but also introduces substantial market risk and earnings volatility tied to digital assets. The company’s future will hinge on how well it can turn supply agreements and distribution relationships into real operating income, and how prudently it manages the crypto treasury. Overall, this is a story of high strategic change and elevated uncertainty, with the past financials offering limited guidance on what the new model will actually deliver.